Ultralife Corp Files 8-K/A Amendment

Ticker: ULBI · Form: 8-K/A · Filed: Jan 16, 2025 · CIK: 875657

Ultralife Corp 8-K/A Filing Summary
FieldDetail
CompanyUltralife Corp (ULBI)
Form Type8-K/A
Filed DateJan 16, 2025
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.10
Sentimentneutral

Sentiment: neutral

Topics: amendment, financial-statements, exhibits

TL;DR

Ultralife Corp filed an amendment to its 8-K. No new info in this snippet.

AI Summary

Ultralife Corporation filed an amendment (8-K/A) on January 16, 2025, to its report originally dated October 31, 2024. The amendment pertains to financial statements and exhibits, with no specific new financial details or material events disclosed in the provided text.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be important for investors to review for accuracy.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous report and does not introduce new material information or significant changes based on the provided text.

Key Players & Entities

  • ULTRALIFE CORP (company) — Registrant
  • October 31, 2024 (date) — Date of Earliest Event Reported
  • January 16, 2025 (date) — Filing Date
  • Delaware (location) — State of incorporation
  • Newark, New York (location) — Principal executive offices

FAQ

What is the purpose of this 8-K/A filing?

This filing is an amendment (Amendment No. 1) to a previous Form 8-K, specifically related to financial statements and exhibits.

What was the original report date being amended?

The original report date being amended was October 31, 2024.

When was this amendment filed with the SEC?

This amendment was filed on January 16, 2025.

What is the company's principal executive office address?

The company's principal executive office is located at 2000 Technology Parkway, Newark, New York 14513.

What is Ultralife Corporation's state of incorporation?

Ultralife Corporation is incorporated in Delaware.

Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-01-16 16:00:38

Key Financial Figures

  • $0.10 — rsuant to Section 12(b): Common Stock, $0.10 par value per share ULBI NASDAQ (

Filing Documents

01 Financial Statements, Pro Forma Financials and Exhibits

Item 9.01 Financial Statements, Pro Forma Financials and Exhibits (a) Financial Statements of Business Acquired 1. Audited combined financial statements of Electrochem as of December 31, 2023 and for the year then ended are attached hereto as Exhibit 99.2 and incorporated herein by reference. 2. Unaudited combined financial statements of Electrochem as of September 27, 2024 and for the nine-month fiscal period then ended are attached hereto as Exhibit 99.3 and incorporated herein by reference. (b) Pro Forma Financial Information Unaudited pro forma combined financial information as of September 30, 2024 and for the nine-month period then ended, and for the year ended December 31, 2023, and notes thereto, is attached hereto as Exhibit 99.4 and incorporated herein by reference. (d) Exhibits Exhibit Number Exhibit Description 10.1 Stock Purchase Agreement by and between GREATBATCH LTD. and ULTRALIFE CORPORATION* 10.2 Credit and Security Agreement among, Ultralife, Southwest Electronic Energy Corporation – an Ultralife Company, a Texas corporation, CLB, Inc., Excell Battery Corporation USA, and Electrochem Solutions, Inc., as borrowers, and certain other subsidiaries of the Company, and KeyBank National Association, as lender and administrative agent** 23.1 Consent of Freed Maxick P.C. (f/k/a Freed Maxick CPAs, P.C.), Independent Registered Public Accounting Firm*** 99.1 Press Release of Ultralife Corporation dated September 30, 2024* 99.2 Audited combined financial statements of Electrochem as of December 31, 2023 and for the year then ended*** 99.3 Unaudited combined financial statements of Electrochem as of September 27, 2024 and for the nine-month fiscal period then ended*** 99.4 Unaudited pro forma combined financial information as of September 30, 2024 and for the nine-month period then ended, and for the year ended December 31, 2023, and notes thereto*** 104 Cover Page Interactive Data File (embedded within the Inline XBRL do

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 16, 2025 ULTRALIFE CORPORATION By: /s/ Philip A. Fain Philip A. Fain

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.